Home > Resources > Whitepapers > Mortality Data in Healthcare Analytics

Mortality Data in Healthcare Analytics

June 19, 2018

The incorporation of mortality data into healthcare data sets allows fraud prevention, accurate billing, and benefits distribution, and true outcome analysis (especially in fatal disease areas like oncology, where survival is a key endpoint). The net effect of adding mortality data is strengthening identity protection, reducing healthcare costs, and improving health treatments and care delivery. However, most healthcare data streams do not inherently capture mortality, and changes to the Social Security Administration’s (SSA) Death Master File (DMF), a leading public data source for mortality records, have dramatically reduced this file’s coverage from 2.5 million lives in 2010 to 460,000 lives in 2016

Spotlight

Advance Medical, Inc.

Advance Medical is an extraordinary benefit offered by the world's leading companies. Physicians are at the heart of Advance Medical's service. From initial intake until the case is closed, members have direct access to their doctor. It is this continuous physician-member relationship that creates the ultimate experience of advocacy and support in times of medical crisis. Founded in 1999, Advance Medical employs 800 dedicated health professionals, including 450 medical doctors who collaborate with leading experts across the globe in every sector of medicine to improve patient care.

OTHER WHITEPAPERS

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Measuring the COVID Effect on Clinical Trials

whitePaper | June 27, 2022

As the world begins its transition into a postpandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Asia Pacific – Clinical trial landscape

whitePaper | November 8, 2022

The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.

Application Notes & Whitepapers 2019

whitePaper | December 19, 2019

Welcome to European Pharmaceutical Review’s Application Notes & Whitepapers Supplement 2019. This year’s topics range from analytical techniques for bioprocess investigation, host cell protein analysis and Raman imaging to advice on outsourcing services for product characterisation.

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Mortality Data in Healthcare Analytics